Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer

Creative Commons License

ERTÜRK Z., BÜBER E., Ozen H., ÇELİKBIÇAK Ö., SALİH B., Acan N. L.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.16, sa.3, ss.70-76, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/uob.905
  • Dergi Adı: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.70-76
  • Anahtar Kelimeler: Mycobacterium brumae, non-muscle invasive bladder cancer, high performance liquid chromatography, matrix-assisted laser desorption/ionization-mass spectrometry, tumour necrosis factor-alpha, BACILLUS-CALMETTE-GUERIN, INVASIVE UROTHELIAL CARCINOMA, CELL-WALL, BCG THERAPY, BOVIS BCG, GUIDELINES, MANAGEMENT, TUMOR
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: Immunotherapy with intravesical Bacillus Calmette-Guerin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain.